Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study

European Journal of Cancer

Volumn 101, Issue , 2018, Pages 201-209

  Horn, Leora ^a   Gettinger, Scott N ^b   Gordon, Michael S ^c   Herbst, Roy S ^b   Gandhi, Leena ^d   Felip, Enriqueta ^e   Sequist, Lecia V ^f   Spigel, David R ^g   Antonia, Scott J ^h   Balmanoukian, Ani ⁱ   Cassier, Philippe A ^j   Liu, Bo ^k   Kowanetz, Marcin ^k   O'Hear, Carol ^k   Fassò, Marcella ^k   Grossman, William ^k   Sandler, Alan ^k   Soria, Jean Charles ^l  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b YALE CANCER CENTER   (United States)

^c HonorHealth and the Scottsdale Lincoln Health Network   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^g SARAH CANNON RESEARCH INSTITUTE   (United States)

^h H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁱ Angeles Clinic and Research Institute   (United States)

^j CENTRE LÉON BÉRARD   (France)

^k GENENTECH INC   (United States)

^l UNIVERSITÉ PARIS SACLAY   (France)

more..

Author keywords

Atezolizumab; Immune checkpoint inhibitor; Non small cell lung cancer; PD L1

Indexed keywords

ATEZOLIZUMAB; BIOLOGICAL MARKER; PROGRAMMED DEATH 1 LIGAND 1; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADULT; ADVERSE EVENT; AGED; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER SURVIVAL; COHORT ANALYSIS; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; HYPONATREMIA; HYPOXIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; UPPER RESPIRATORY TRACT INFECTION; VOMITING; BIOSYNTHESIS; CHEMICALLY INDUCED; CLINICAL TRIAL; GENETICS; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; B7-H1 ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; FATIGUE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NAUSEA; NEOPLASM METASTASIS; YOUNG ADULT;

EID: 85050803951     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2018.06.031     Document Type: Article

References (20)

1. Dong, H., Strome, S.E., Salomao, D.R., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8 (2002), 793–800.
2. Herbst, R.S., Soria, J.C., Kowanetz, M., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515 (2014), 563–567.
3. Brown, J.A., Dorfman, D.M., Ma, F.R., et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 170 (2003), 1257–1266.
4. Latchman, Y., Wood, C.R., Chernova, T., et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2 (2001), 261–268.
5. Powles, T., Eder, J.P., Fine, G.D., et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515 (2014), 558–562.
6. Chen, D.S., Irving, B.A., Hodi, F.S., Molecular pathways: next-generation immunotherapy–inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res 18 (2012), 6580–6587.
7. Zou, W., Wolchok, J.D., Chen, L., PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med, 8, 2016 328rv4.
8. National Comprehensive Cancer Network, NCCN clinical Practice guidelines in Oncology. Non-small cell lung cancer. V2.2018. December 19, 2017. 2017 Available at: https://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf. (Accessed 20 December 2017)
9. Akbari, O., Stock, P., Singh, A.K., et al. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions. Mucosal Immunol 3 (2010), 81–91.
10. Matsumoto, K., Fukuyama, S., Eguchi-Tsuda, M., et al. B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma. Biochem Biophys Res Commun 365 (2008), 170–175.
11. Rittmeyer, A., Barlesi, F., Waterkamp, D., et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389 (2017), 255–265.
12. Fehrenbacher, L., Spira, A., Ballinger, M., et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387 (2016), 1837–1846.
13. Borghaei, H., Paz-Ares, L., Horn, L., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 (2015), 1627–1639.
14. Borghaei, H., Brahmer, J.R., Horn, L., et al. Nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced NSCLC: CheckMate 017/057 2-y update and exploratory cytokine profile analyses. J Clin Oncol, 34(suppl), 2016 Abstr 9025.
15. Herbst, R.S., Baas, P., Kim, D.W., et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387 (2016), 1540–1550.
16. Hanna, N., Shepherd, F.A., Fossella, F.V., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 (2004), 1589–1597.
17. Peters, S., Gettinger, S., Johnson, M.L., et al. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH). J Clin Oncol 35 (2017), 2781–2789.
18. Gettinger, S.N., Horn, L., Gandhi, L., et al. Overall survival and long-term safety of nivolumab (Anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 33 (2015), 2004–2012.
19. Garon, E.B., Rizvi, N.A., Hui, R., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372 (2015), 2018–2028.
20. Rizvi, N.A., Hellmann, M.D., Snyder, A., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128.